No abstract

No abstract

Objective Recent data suggest patients with epithelial ovarian cancers on statin therapy have improved survival. We have hypothesized that statins influence ovarian cancer outcome through alteration of lipoprotein profiles, and sought to determine correlations between lipoprotein levels and survival in women with advanced stage disease. Methods After IRB approval, we identified patients with stage IIIC/IV epithelial ovarian cancer with banked prediagnostic fasting serum. Serum was assayed for levels of total cholesterol (TC), high-density lipoprotein (HDL), and triglycerides (TG). LDL was calculated by subtraction of TG/5 and HDL from TC. Data were examined using Fisher's exact, Kaplan–Meier, and Cox regression analyses. Results One hundred thirty-two patients were studied. Twenty-six percent of patients had elevated LDL; 18% had elevated TC; 32% had elevated TG; and 48% had elevated HDL. No univariate associations were identified between elevated TC, HDL, TG, LDL and age, stage IV disease, high grade, or optimal cytoreduction. Median progression-free survival for patients with normal LDL levels was 27 months, compared to 12 months for patients with elevated LDL (p = 0.0004). Overall disease-specific survival was longer for patients with normal LDL levels (59 months) compared to those with elevated LDL (51 months, p = 0.04). Multivariate analysis indicated that LDL retained significance as an independent predictor of survival, after controlling for age, stage, grade, and suboptimal cytoreduction (p = 0.003). Conclusions These data suggest LDL is a significant predictor of clinical outcome, and warrant the further study of lipoproteins and statins on epithelial ovarian cancer biology.

In Experiment 1, 12 lactating Holstein cows were provided drinking water of either 10.6 or 27.0 degrees C for 24 h/d in a changeover design to examine the effects of water temperature on feed intake, water intake, respiration rate, rectal temperature, plasma thyroid hormone concentration, and milk yield. The 1st wk of each 3-wk treatment period was for adjustment and the next 2 wk were comparison periods. Least squares means for DM intake as a percentage of body weight were 3.68 and 3.57 for 10.6 and 27.0 degrees C treatment groups. Water intakes in liters per kilogram of dry feed consumed as a percentage of body weight were 21.3 and 20.3. Respiration rates were 70.5 and 81.0 breaths per minute; rectal temperatures were 39.7 and 39.9 degrees C, Triiodothyronine averaged .88 and .75 ng/ml; thyroxine, 42.4 and 39.2 ng/ml; cortisol, 3.03 and 2.06 ng/ml; and progesterone in milk, 4.58 and 3.15 ng/ml for the 10.6 and 27.0 degrees C treatment groups. Milk yield averaged 25.9 and 24.7 kg/d and FCM averaged 25.6 and 23.6 kg/d, respectively. In Experiment 2, 24 cows given a choice of chilled or warm water showed a clear preference (about 98%) for the warm water. If cows are given chilled water of 10 degrees C continuously, no warm drinking water should be available. Chilled drinking water lowered respiration rates and body temperatures and increased feed intake and milk yield.

The objective was to determine the relationship of prior follicular development to GnRH-induced cyclic ovarian activity in dairy cows postpartum. Sixty lactating Holstein and Guernsey cows from the University of Missouri dairy herds were assigned at random to one of two groups. Group I consisted of 20 cows (control) given a single intramuscular (IM) injection of saline. Group II consisted of 40 cows given a single injection of 100 micrograms gonadotropin releasing hormone (GnRH) IM. Treatments were administered 12 to 14 days postpartum. All cows were palpated per rectum to monitor ovarian activity prior to treatment (time 0) and 2 to 3 and 7 to 9 days post-treatment. Blood was collected via tail vessel puncture at time 0 and 7 to 9 days post-treatment. The percentage of cows exhibiting a follicle 10 mm or greater in diameter prior to treatment was not different between Group I (50%) and Group II (43%). However, twenty (50%) of the GnRH-treated cows initiated cyclic ovarian activity following treatment as evidenced by palpable CL and plasma progesterone greater than or equal to 1.0 ng/ml on day 9 post-treatment in contrast to only four (20%) saline-treated cows (P less than 0.05). Seventeen of 20 cows ovulating in Group II exhibited a palpable follicle greater than or equal to 10 mm in diameter prior to treatment compared to 3 of 4 cows in Group I. Prior to treatment, plasma concentrations of LH, estradiol-17 beta and progesterone were not different (P less than .05) between cows in Groups I and II. In Group II, preinjection levels of estradiol-17 beta and LH for cows ovulating in response to GnRH were higher (P less than .01) than in cows not ovulating. Postinjection concentrations of progesterone in plasma on days 7 to 9 were higher (P less than .01) in cows ovulating than in cows not ovulating. Six (30%) cows in Group I developed ovarian cysts prior to conception as compared to 12.5% (5) of the cows in Group II (P less than .05). The present study suggests: (1) GnRH treatment as early as 12 to 14 days postpartum may initiate cyclic ovarian activity in normal dairy cows; (2) elevated preinjection concentrations of estradiol-17 beta and follicular growth are important for GnRH induced ovulations; and (3) GnRH treatment 12 to 14 days postpartum may be useful in reducing abnormal ovarian activity.